[Congressional Record Volume 167, Number 145 (Tuesday, August 10, 2021)]
[Senate]
[Page S6399]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 3700. Ms. HASSAN submitted an amendment intended to be proposed by 
her to the concurrent resolution S. Con. Res. 14, setting forth the 
congressional budget for the United States Government for fiscal year 
2022 and setting forth the appropriate budgetary levels for fiscal 
years 2023 through 2031; which was ordered to lie on the table; as 
follows:

       At the end of title III, add the following:

     SEC. 3___. RESERVE FUND RELATING TO INCREASING DRUG REBATE 
                   TRANSPARENCY UNDER MEDICARE PART D.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     increasing drug pricing transparency, which may include 
     requiring mandatory reporting and public disclosure of all 
     rebates, discounts, price concessions, and formulary 
     placements for any covered part D drug for which such 
     rebates, discounts, or price concessions are passed to 
     beneficiaries at the point of sale, by the amounts provided 
     that such legislation would not increase the deficit over the 
     period of the total of fiscal years 2022 through 2031.
                                 ______